A novel mechanism for the immunomodulatory functions of class II MHC-derived peptides

Journal of the American Society of Nephrology

Volumn 14, Issue 4, 2003, Pages 1053-1065

  Murphy, Barbara ^a   Yu, Joyce ^a   Jiao, Qingsheng ^a   Lin, Marvin ^a   Chitnis, Tanuja ^b   Sayegh, Mohamed H ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CASPASE; HLA DQA1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ALLOIMMUNITY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG MECHANISM; GENETIC CONSERVATION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0037379447     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000057541.69641.F8     Document Type: Article

References (45)

1. Reinherz EL, Tan K, Tang L, Kern P, Liu J, Xiong Y, Hussey RE, Smolyar A, Hare B, Zhang R, et al: The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286: 1913-1921, 1999
2. Sloan-Lancaster J, Evavold B, Allen P: Induction of T-cell allergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363: 156-159, 1993
3. Verhoef A, Lamb JR: Threshold signaling of human Th0 cells in activation and anergy: modulation of effector function by altered TCR ligand. J Immunol 164: 6034-6040, 2000
4. Young DA, Lowe LD, Booth SS, Whitters MJ, Nicholson L, Kuchroo VK, Collins M: IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J Immunol 164: 3563-3572, 2000
5. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK: An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3: 397-405, 1995
6. Colovai AI, Liu Z, Harris PE, Cortesini R, Suciu-Foca N: Allopeptide-specific T cell reactivity altered by peptide analogs. J Immunol 158: 48-54, 1997
7. Liu Z, Harris PE, Colovai AI, Reed EF, Maffei A, Suciu-Foca N: Suppression of the indirect pathway of T cell reactivity by high zone tolerance. Autoimmunity 21: 173-184, 1995
8. Magee CC, Sayegh MH: Peptide-mediated immunosuppression. Curr Opin Immunol 9: 669-675, 1997
9. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, Strominger JL: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358: 764-768, 1992
10. Williams CB, Vidal K, Donermeyer D, Peterson DA, White JM, Allen PM: In vivo expression of a TCR antagonist: T cells escape central tolerance but are antagonized in the periphery. J Immunol 161: 128-137, 1998
11. Murphy B, Krensky AM: HLA-derived peptides as novel immunomodulatory therapeutics. J Am Soc Nephrol 10: 1346-1355, 1999
12. Sayegh MH, Turka LA: T cell costimulatory pathways: Promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 6: 1143-1150, 1995
13. Jameson BA, McDonnell JM, Marini JC, Korngold R: A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 368: 744-746, 1994
14. Koch U, Korngold R: A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers. Blood 89: 2880-2890, 1997
15. Murphy B, Magee CC, Alexander SI, Waaga AM, Snoeck HW, Vella JP, Carpenter CB, Sayegh MH: Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J Clin Invest 103: 859-867, 1999
16. Murphy B, Auchincloss Jr H, Carpenter CB, Sayegh MH: T cell recognition of xeno-MHC peptides during concordant xenograft rejection. Transplantation 61: 1133-1137, 1996
17. Jenkins MK, Pardoll DM, Mizuguchi J, Quill H, Schwartz RH: T-cell unresponsiveness in vivo and in vitro: Fine specificity of induction and molecular characterization of the unresponsive state. Immunol. Rev. 95: 113, 1987
18. Budihardjo, I., Oliver H, Lutter M, Luo X, Wang X: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15: 269-290, 1999
19. Owen-Schaub LB, Yonshara S, Crump III, WL, Grimm EA: DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 140: 1992
20. Gonin S, Diaz-Latoud C, Richard MJ, Ursini MV, Imbo A, Manero F, Arrigo A-P: p53/T-antigen complex disruption in T-antigen transformed NIH3T3 fibroblasts exposed to oxidative stress: Correlation with the appearance of a Fas/APO-1/CD95 dependent, caspase independent, necrotic pathway. Oncogene 18: 8011-8023, 1999
21. Bertho N, Drenou B, Laupeze B, Berre CL, Amiot L, Grosset JM, Fardel O, Charron D, Mooney N, Fauchet R: HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC. J Immunol 164: 2379-2385, 2000
22. Lesage S, Steff AM, Phillippoussis F, Page M, Trop S, Mateo V, Hugo P: CD4+ CD8+ thymocytes are preferentially induced to die following CD45 cross-linking, through a novel apoptotic pathway. J Immunol 159: 4762, 1997
23. Pettersen RD, Hestdal K, Olafsen MK, Lie SO, Lindberg FP: CD47 signals T cell death. J Immunol 162: 7031-7040, 1999
24. Pettersen RD, Bernard G, Olafsen MK, Pourtein M, Lie SO: CD99 signals caspase-independent T cell death. J Immunol 166: 4931-4942, 2001
25. Petterson RD, Gaudernack, G, Olafsen MK, Lie SO, Hestdal K: The TCR-binding region of the HLA class I a2 domain signals rapid Fas-independent cell death: A direct pathway for T cell-mediated killing of target cells. J Immunol 160: 4343-4352, 1998
26. Tepper AD, de Vries E, van Blitterswijk WJ, Borst J: Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis [published erratum appears in J Clin Invest 103: 1363, 1999]. J Clin Invest 103: 971-978, 1999
27. Green D, Kroemer G: The central executioners of apoptosis: Caspases or mitochondria? Trends Cell Biol 8: 267-271, 1998
28. Zavazava N, Kronke M: Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 2: 1005-1010, 1996
29. Woodle ES, Smith DM, Bluestone JA, Kirkman WM 3rd, Green DR, Skowronski EW: Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. J Immunol 158: 2156-2164, 1997
30. Genestier L, Meffre G, Garrone P, Pin JJ, Liu YJ, Banchereau J, Revillard JP: Antibodies to HLA class I alpha1 domain trigger apoptosis of CD40-activated human B lymphocytes. Blood 90: 726-735, 1997
31. Genestier L, Paillot R, Bonnefoy-Berard N, Meffre G, Flacher M, Fevre D, Liu YJ, Le Bouteiller P, Waldmann H, Engelhard VH, et al: Fas-independent apoptosis of activated T cells induced by antibodies to the HLA class I alpha1 domain. Blood 90: 3629-3639, 1997
32. Drenou B, Blancheteau V, Burgess DH, Fauchet R, Charron DJ, Mooney NA: A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes. J Immunol 163: 4115-4124, 1999
33. Reinherz EL, Tan K, Tang L, Kern P, Liu J-H, Xiong Y, Hussey RE: The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286: 1913-1925, 1999
34. Doyle IS, Hollmann CA, Crispe IN, Owens T: Specific blockade by CD54 and MHC II of CD40-mediated signaling for B cell proliferation and survival. Exp Cell Res 265: 312-318, 2001
35. Ding L, Shevach EM: Differential effects of CD28 engagement and IL-12 on T cell activation by altered peptide ligands. J Immunol 161: 6614-6621, 1998
36. Murphy B, Sayegh MH: Why do we reject a graft? Mechanisms of recognition of transplantation. Transplant Rev 10: 150-159, 1996
37. Womer KL, Sayegh MH, Auchincloss H Jr: Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Philos Trans R Soc Lond B Biol Sci 356: 639-647, 2001
38. Vella JP, Ferreira M, Murphy B, Alexander S, Sayegh MH, Carpenter CB: Indirect allorecognition of MHC allopeptides in human renal allograft recipients with chronic graft dysfunction. Transplantation 64: 795-800, 1997
39. Crespo M, Pascual M, Tolkoff-Rubin N, Mauiyyedi S, Collins AB, Fitzpatrick D, Farrell ML, Williams WW, Delmonico FL, Cosimi AB, et al: Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 71: 652-658, 2001
40. Paul LC: Antibodies and chronic organ graft rejection. Ann Transplant 2: 46-52, 1997
41. Prommool S, Jhangri GS, Cockfield SM, Halloran PF: Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 11: 565-573, 2000
42. Wolfe RA, Ashby VB, Milford EL, Bloembergen WE, Agodoa LY, Held PJ, Port FK: Differences in access to cadaveric renal transplantation in the United States. Am J Kidney Dis 36: 1025- 1033, 2000
43. Cascalho M, Platt JL: The immunological barrier to xenotransplantation. Immunity 14: 437-446, 2001
44. Giral M, Cuturi MC, Nguyen JM, Josien R, Dantal J, Floc'h R, Buelow R, Pouletty P, Soulillou JP: Decreased cytotoxic activity of natural killer cells in kidney allograft recipients treated with human HLA-derived peptide. Transplantation 63: 1004-1011, 1997
45. DeBruyne LA, Li K, Chan SY, Bishop KD, Bromberg JS: Lipid-mediated gene transfere of viral IL-10 prolongs vascularized allograft survival by inhibiting dono-speicifc cellular and humoral immune responses. Gene Therapy 7: 575-582, 2000